NEXT GENERATION ECM-BASED ALLOGRAFT TECHNOLOGY: Potent biological scaffolds strategically control stem cell fate and function, allowing our allografts to harness the regenerative potential of patient s own stem cells and improve surgical outcomes. 1 2015 Lattice Biologics Inc. All Rights Reserved.
TISSUE ENGINEERING & REGENERATIVE MEDICINE Tissue Structure: The majority of living tissue s volume is comprised of extracellular space between groups of tightly packed cells. This void is filled with a complex meshwork called the Extracellular Matrix. Extracellular Matrix (ECM): A dynamic, physiologically active structure of molecules secreted by cells that provides structural and biochemical support to surrounding cells and is a component of all living tissues. Provides structural support for cells within tissue. Guides cells division, growth, and development. Determines how tissues look and function. Stem Cells - Powerful Agents of Healing: Tissue repair requires the recruitment of properly functioning stem cells to the wound location. They release growth factor proteins that speed up and enhance healing. Ability to regenerate and differentiate into different types of cells (pluripotency) offers incredible therapeutic potential for tissue engineering. Both ECM and Stem Cells are essential for growth and wound healing processes. 2 2015 Lattice Biologics Inc. All Rights Reserved.
TISSUE ENGINEERING & REGENERATIVE MEDICINE Decellularization: Biomedical engineering process that isolates a tissue s ECM from its inhabiting cells, leaving an ECM scaffold of the original tissue. Creates a natural biomaterial to act as a scaffold for cell growth, differentiation and tissue development. Can be recellularized with a patient s own cells for tissue regeneration to eliminate adverse immune response and rejection of donor tissue allografts. Benefits of Deceullarized Stem Cell Matrix (DSCM) DSCM offers an effective biological scaffold for controlling stem cell fate and function during tissue organization. Stem cells interact with and respond to signals and cues emanating from their ECM. Lattice Biologics recognizes that the ability to channel the regenerative potential of stem cells through decellularized ECM-based scaffolds is the future of tissue-regenerative medicine. 3 2015 Lattice Biologics Inc. All Rights Reserved.
SHORTCOMINGS IN THE REGENERATIVE MEDICINE MARKET The major limitation of existing stem cell therapies is low adhesion and engraftment to sites of injury. Current donor tissue (allograft) products for bone, skin, and cartilage regeneration rely on undirected ECM scaffolds. They lack the ability to promote effective regeneration and often do not take or are rejected by the patient s immune system. CURRENT UNDIRECTED ALLOGRAFT PRODUCTS ON THE MARKET Do Not Adequately Harness Healing Potential Undirected acellular scaffolds are only a temporary void filler for tissue defects. They DO NOT: Engage cells in healing the wound site. Direct cells to regenerate intelligently as a specific tissue type (such as bone vs. skin). Take or heal wounds properly most of the time. Limited by the Quality of Patients own Stem Cells Stem cells are critical to tissue regeneration and wound healing. Over time, senescence (biological aging) erodes stem cells reparative qualities by reducing the natural homing abilities that enable them to migrate to wound sites, adhere, engraft (establish residence), and begin healing. This renders traditional allograft products ineffective for many. 4 2015 Lattice Biologics Inc. All Rights Reserved.
SOLUTION: NEXT GENERATION ECM ALLOGRAFT TECHNOLOGY Lattice Biologics Modified Extracellular Matrix is Directed Scaffold Technology derived from native ECM secreted by human Mesenchymal Stem Cells (hmsc) and enhanced for optimal regeneration, differentiation, homing, and engraftment. This dramatically improves healing capacity and reduces surgical recovery times. Human-sourced (as opposed to porcine) ECM is infused into allograft materials to synergize their healing potential. LATTICE BIOLOGICS ECM-BASED TECHNOLOGY Differentiation HMSCs possess the powerful potential to differentiate into any type of tissue. Undirected allograft products do not harness this potential. Lattice strategically applies modifiers of MSC gene expression to ECM to create directed scaffolds that direct hmscs to differentiate and regenerate as the intended bone, skin, or cartilage cells. Optimized growth conditions to promote propagation and intentional differentiation. Homing and Engraftment Decellularized cement provides a microenvironment that is engineered to enhance the ability of stem cells to adhere (engraft) and thrive. Lattice s ECM technology serves as a reservoir of proteins and growth factors that provide targeted tissue engineering treatment through the use of signaling markers that attract hmscs to the site of injury (homing). 5 2015 Lattice Biologics Inc. All Rights Reserved.
HOW OUR ECM TECHNOLOGY IMPROVES ALLOGRAFTS SHORTCOMINGS OF THE MARKET S CURRENT UNDIRECTED SCAFFOLD ALLOGRAFT PRODUCTS Inadequate Healing and Patient Outcomes These products serve only as temporary void fillers for tissue and do not actively promote healing or specific cellular regeneration (such as: bone vs. skin) at the wound/surgical site. Because these products do not actively promote regeneration, they depend solely on the quality of the Patients own stem cells for healing, which is often ineffective. BENEFITS OF LATTICE BIOLOGICS NEXT GENERATION ECM-BASED ALLOGRAFTS Dramatically Improved Healing and Reduced Recovery Times Lattice s technology is derived from native ECM secreted by human Mesenchymal Stem Cells (hmsc) and allows our allograft products to: strategically differentiate as bone, skin, or cartilage cells actively promote patient healing and specific cellular regeneration Lattice s decellularized ECM provides a microenvironment engineered to promote the ability of patients stem cells to adhere to the allograft and thrive. Through specific proteins and growth factors, we utilize signaling markers that attract patients stem cells to the injury site to promote healing. 6 2015 Lattice Biologics Inc. All Rights Reserved.